Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?

LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.
Open original source
LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.
Open original source